BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer

Opinion
Video

An overview of the design and rationale for the phase 2 BRIDGET study looking at the addition of tucatinib to HER2-directed antibody therapy in breast cancer.

Recent Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Related Content